id CRUZ_6ca0fbc682f773b08300049b43907199
oai_identifier_str oai:www.arca.fiocruz.br:icict/50746
network_acronym_str CRUZ
network_name_str Repositório Institucional da FIOCRUZ (ARCA)
repository_id_str 2135
spelling Andrade, Ana Cláudia dos Santos PereiraSilva, Gabriel Henrique CampolinaQueiroz Junior, Celso MartinsOliveira, Leonardo Camilo deLacerda, Larisse de Souza BarbosaGaggino, Jordane Clarisse PimentaSouza, Filipe Resende Oliveira deChaves, Ian de MeiraPassos, Ingredy BeatrizTeixeira, Danielle CunhaSilva, Paloma Graziele BittencourtValadão, Priscila Aparecida CostaOliveira, Leonardo RossiAntunes, Maisa MotaFigueiredo, André Felipe AlmeidaWnuk, Natália TeixeiraTemerozo, Jairo RamosFerreira, André CostaCramer, AllyssonOliveira, Cleida AparecidaCarvalho, Ricardo DurãesArns, Clarice WeisGuimarães, Pedro Pires GoulartCosta, Guilherme Mattos JardimMenezes, Gustavo Batista deGuatimosim, CristinaSilva, Glauber Santos Ferreira daSouza, Thiago Moreno L.Barrioni, Breno RochaPereira, Marivalda de MagalhãesSousa, Lirlândia Pires deTeixeira, Mauro MartinsCosta, Vivian Vasconcelos2022-01-13T12:56:44Z2022-01-13T12:56:44Z2021ANDRADE, Ana Cláudia dos SantosPereira et al. A Biosafety Level 2 Mouse Model for Studying Betacoronavirus- Induced Acute Lung Damage and Systemic Manifestations. Journal of Virology, v. 95, n. 22, e01276-21, p. 1-18, Nov. 2021.1098-5514https://www.arca.fiocruz.br/handle/icict/5074610.1128/JVI.01276-210022-538XengAmerican Society for MicrobiologyBetacoronavírusMHV-3Infecção pulmonarCOVID-19Modelo animalFator de necrose tumoralBetacoronavirusMHV-3Lung infectionCOVID-19Animal modelTumor necrosis factorA Biosafety Level 2 Mouse Model for Studying Betacoronavirus- Induced Acute Lung Damage and Systemic Manifestationsinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleUniversidade Federal de Minas Gerais. Instituto de Ciências Biológicas. Departamento de Morfologia. Belo Horizonte, MG, Brasil.Universidade Federal de Minas Gerais. Instituto de Ciências Biológicas. Departamento de Bioquímica e Imunologia. Belo Horizonte, MG, Brasil.Universidade Federal de Minas Gerais. Instituto de Ciências Biológicas. Departamento de Morfologia. Belo Horizonte, MG, Brasil.Universidade Federal de Minas Gerais. Instituto de Ciências Biológicas. Departamento de Morfologia. Belo Horizonte, MG, Brasil.Universidade Federal de Minas Gerais. Instituto de Ciências Biológicas. Departamento de Morfologia. Belo Horizonte, MG, Brasil.Universidade Federal de Minas Gerais. Instituto de Ciências Biológicas. Departamento de Morfologia. Belo Horizonte, MG, Brasil.Universidade Federal de Minas Gerais. Instituto de Ciências Biológicas. Departamento de Morfologia. Belo Horizonte, MG, Brasil.Universidade Federal de Minas Gerais. Instituto de Ciências Biológicas. Departamento de Morfologia. Belo Horizonte, MG, Brasil.Universidade Federal de Minas Gerais. Instituto de Ciências Biológicas. Departamento de Microbiologia. Belo Horizonte, MG, Brasil.Universidade Federal de Minas Gerais. Instituto de Ciências Biológicas. Departamento de Morfologia. Belo Horizonte, MG, Brasil.Universidade Federal de Minas Gerais. Instituto de Ciências Biológicas. Departamento de Fisiologia e Biofísica. Belo Horizonte, MG, Brasil.Universidade Federal de Minas Gerais. Instituto de Ciências Biológicas. Departamento de Morfologia. Belo Horizonte, MG, Brasil.Universidade Federal de Minas Gerais. Instituto de Ciências Biológicas. Departamento de Morfologia. Belo Horizonte, MG, Brasil.Universidade Federal de Minas Gerais. Instituto de Ciências Biológicas. Departamento de Morfologia. Belo Horizonte, MG, Brasil.Universidade Federal de Minas Gerais. Instituto de Ciências Biológicas. Departamento de Morfologia. Belo Horizonte, MG, Brasil.Universidade Federal de Minas Gerais. Instituto de Ciências Biológicas. Departamento de Morfologia. Belo Horizonte, MG, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Pesquisa sobre o Timo. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Instituto Nacional de Ciência e Tecnologia em Neuroimunomodulação. Rio de Janeiro, RJ, Brasil.Fundação Oswaldo Cruz. Centro de Desenvolvimento Tecnológico em Saúde. Instituto Nacional de Ciência e Tecnologia em Inovação em Doenças de Populações Negligenciadas. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil / Universidade Iguaçu. Laboratório de Pesquisas Pre-Clínicas. Nova Iguaçu, RJ, Brasil.Universidade Federal de Minas Gerais. Instituto de Ciências Biológicas. Departamento de Bioquímica e Imunologia. Belo Horizonte, MG, Brasil.Universidade Federal de Minas Gerais. Instituto de Ciências Biológicas. Departamento de Morfologia. Belo Horizonte, MG, Brasil.Universidade Estadual de Campinas, Laboratório de Virologia. Campinas, SP, Brasil.Universidade Estadual de Campinas, Laboratório de Virologia. Campinas, SP, Brasil.Universidade Federal de Minas Gerais. Instituto de Ciências Biológicas. Departamento de Fisiologia e Biofísica. Belo Horizonte, MG, Brasil.Universidade Federal de Minas Gerais. Instituto de Ciências Biológicas. Departamento de Morfologia. Belo Horizonte, MG, Brasil.Universidade Federal de Minas Gerais. Instituto de Ciências Biológicas. Departamento de Microbiologia. Belo Horizonte, MG, Brasil.Universidade Federal de Minas Gerais. Instituto de Ciências Biológicas. Departamento de Microbiologia. Belo Horizonte, MG, Brasil.Universidade Federal de Minas Gerais. Instituto de Ciências Biológicas. Departamento de Microbiologia. Belo Horizonte, MG, Brasil.Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Instituto Nacional de Ciência e Tecnologia em Neuroimunomodulação. Rio de Janeiro, RJ, Brasil / Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Laboratório de Imunofarmacologia. Rio de Janeiro, RJ, Brasil.Universidade Federal de Minas Gerais. Escola de Engenharia. Departamento de Engenharia Metalúrgica e Materiais. Belo Horizonte, MG, Brasil.Universidade Federal de Minas Gerais. Escola de Engenharia. Departamento de Engenharia Metalúrgica e Materiais. Belo Horizonte, MG, Brasil.Universidade Federal de Minas Gerais. Faculdade de Farmácia. Departamento de Análises Clínicas e Toxicológicas. Belo Horizonte, MG, Brasil.Universidade Federal de Minas Gerais. Instituto de Ciências Biológicas. Departamento de Bioquímica e Imunologia. Belo Horizonte, MG, Brasil.Universidade Federal de Minas Gerais. Instituto de Ciências Biológicas. Departamento de Morfologia. Belo Horizonte, MG, Brasil / Universidade Federal de Minas Gerais. Instituto de Ciências Biológicas. Departamento de Bioquímica e Imunologia. Belo Horizonte, MG, Brasil.The emergence of life-threatening zoonotic diseases caused by betacoronaviruses, including the ongoing coronavirus disease 19 (COVID-19) pandemic, has highlighted the need for developing preclinical models mirroring respiratory and systemic pathophysiological manifestations seen in infected humans. Here, we showed that C57BL/6J wild-type mice intranasally inoculated with the murine betacoronavirus murine hepatitis coronavirus 3 (MHV-3) develop a robust inflammatory response leading to acute lung injuries, including alveolar edema, hemorrhage, and fibrin thrombi. Although such histopathological changes seemed to resolve as the infection advanced, they efficiently impaired respiratory function, as the infected mice displayed restricted lung distention and increased respiratory frequency and ventilation. Following respiratory manifestation, the MHV-3 infection became systemic, and a high virus burden could be detected in multiple organs along with morphological changes. The systemic manifestation of MHV-3 infection was also marked by a sharp drop in the number of circulating platelets and lymphocytes, besides the augmented concentration of the proinflammatory cytokines interleukin 1 beta (IL-1b), IL-6, IL-12, gamma interferon (IFN-g), and tumor necrosis factor (TNF), thereby mirroring some clinical features observed in moderate and severe cases of COVID-19. Importantly, both respiratory and systemic changes triggered by MHV-3 infection were greatly prevented by blocking TNF signaling, either via genetic or pharmacologic approaches. In line with this, TNF blockage also diminished the infection- mediated release of proinflammatory cytokines and virus replication of human epithelial lung cells infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Collectively, results show that MHV-3 respiratory infection leads to a large range of clinical manifestations in mice and may constitute an attractive, lower-cost, biosafety level 2 (BSL2) in vivo platform for evaluating the respiratory and multiorgan involvement of betacoronavirus infections. IMPORTANCE Mouse models have long been used as valuable in vivo platforms to investigate the pathogenesis of viral infections and effective countermeasures. The natural resistance of mice to the novel betacoronavirus SARS-CoV-2, the causative agent of COVID-19, has launched a race toward the characterization of SARS-CoV-2 infection in other animals (e.g., hamsters, cats, ferrets, bats, and monkeys), as well as adaptation of the mouse model, by modifying either the host or the virus. In the present study, we utilized a natural pathogen of mice, MHV, as a prototype to model betacoronavirus-induced acute lung injure and multiorgan involvement under biosafety level 2 conditions. We showed that C57BL/6J mice intranasally inoculated with MHV-3 develops severe disease, which includes acute lung damage and respiratory distress that precede systemic inflammation and death. Accordingly, the proposed animal model may provide a useful tool for studies regarding betacoronavirus respiratory infection and related diseases.info:eu-repo/semantics/openAccessreponame:Repositório Institucional da FIOCRUZ (ARCA)instname:Fundação Oswaldo Cruz (FIOCRUZ)instacron:FIOCRUZORIGINALJaime_Temerozo_etal_IOC_2021.pdfJaime_Temerozo_etal_IOC_2021.pdfapplication/pdf7900929https://www.arca.fiocruz.br/bitstream/icict/50746/2/Jaime_Temerozo_etal_IOC_2021.pdf48c0d800e292f2c055dc1db1a34f05c5MD52LICENSElicense.txtlicense.txttext/plain; charset=utf-82991https://www.arca.fiocruz.br/bitstream/icict/50746/3/license.txt5a560609d32a3863062d77ff32785d58MD53icict/507462023-02-13 14:15:42.339oai:www.arca.fiocruz.br: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ório InstitucionalPUBhttps://www.arca.fiocruz.br/oai/requestrepositorio.arca@fiocruz.bropendoar:21352023-02-13T17:15:42Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)false
dc.title.pt_BR.fl_str_mv A Biosafety Level 2 Mouse Model for Studying Betacoronavirus- Induced Acute Lung Damage and Systemic Manifestations
title A Biosafety Level 2 Mouse Model for Studying Betacoronavirus- Induced Acute Lung Damage and Systemic Manifestations
spellingShingle A Biosafety Level 2 Mouse Model for Studying Betacoronavirus- Induced Acute Lung Damage and Systemic Manifestations
Andrade, Ana Cláudia dos Santos Pereira
Betacoronavírus
MHV-3
Infecção pulmonar
COVID-19
Modelo animal
Fator de necrose tumoral
Betacoronavirus
MHV-3
Lung infection
COVID-19
Animal model
Tumor necrosis factor
title_short A Biosafety Level 2 Mouse Model for Studying Betacoronavirus- Induced Acute Lung Damage and Systemic Manifestations
title_full A Biosafety Level 2 Mouse Model for Studying Betacoronavirus- Induced Acute Lung Damage and Systemic Manifestations
title_fullStr A Biosafety Level 2 Mouse Model for Studying Betacoronavirus- Induced Acute Lung Damage and Systemic Manifestations
title_full_unstemmed A Biosafety Level 2 Mouse Model for Studying Betacoronavirus- Induced Acute Lung Damage and Systemic Manifestations
title_sort A Biosafety Level 2 Mouse Model for Studying Betacoronavirus- Induced Acute Lung Damage and Systemic Manifestations
author Andrade, Ana Cláudia dos Santos Pereira
author_facet Andrade, Ana Cláudia dos Santos Pereira
Silva, Gabriel Henrique Campolina
Queiroz Junior, Celso Martins
Oliveira, Leonardo Camilo de
Lacerda, Larisse de Souza Barbosa
Gaggino, Jordane Clarisse Pimenta
Souza, Filipe Resende Oliveira de
Chaves, Ian de Meira
Passos, Ingredy Beatriz
Teixeira, Danielle Cunha
Silva, Paloma Graziele Bittencourt
Valadão, Priscila Aparecida Costa
Oliveira, Leonardo Rossi
Antunes, Maisa Mota
Figueiredo, André Felipe Almeida
Wnuk, Natália Teixeira
Temerozo, Jairo Ramos
Ferreira, André Costa
Cramer, Allysson
Oliveira, Cleida Aparecida
Carvalho, Ricardo Durães
Arns, Clarice Weis
Guimarães, Pedro Pires Goulart
Costa, Guilherme Mattos Jardim
Menezes, Gustavo Batista de
Guatimosim, Cristina
Silva, Glauber Santos Ferreira da
Souza, Thiago Moreno L.
Barrioni, Breno Rocha
Pereira, Marivalda de Magalhães
Sousa, Lirlândia Pires de
Teixeira, Mauro Martins
Costa, Vivian Vasconcelos
author_role author
author2 Silva, Gabriel Henrique Campolina
Queiroz Junior, Celso Martins
Oliveira, Leonardo Camilo de
Lacerda, Larisse de Souza Barbosa
Gaggino, Jordane Clarisse Pimenta
Souza, Filipe Resende Oliveira de
Chaves, Ian de Meira
Passos, Ingredy Beatriz
Teixeira, Danielle Cunha
Silva, Paloma Graziele Bittencourt
Valadão, Priscila Aparecida Costa
Oliveira, Leonardo Rossi
Antunes, Maisa Mota
Figueiredo, André Felipe Almeida
Wnuk, Natália Teixeira
Temerozo, Jairo Ramos
Ferreira, André Costa
Cramer, Allysson
Oliveira, Cleida Aparecida
Carvalho, Ricardo Durães
Arns, Clarice Weis
Guimarães, Pedro Pires Goulart
Costa, Guilherme Mattos Jardim
Menezes, Gustavo Batista de
Guatimosim, Cristina
Silva, Glauber Santos Ferreira da
Souza, Thiago Moreno L.
Barrioni, Breno Rocha
Pereira, Marivalda de Magalhães
Sousa, Lirlândia Pires de
Teixeira, Mauro Martins
Costa, Vivian Vasconcelos
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.contributor.author.fl_str_mv Andrade, Ana Cláudia dos Santos Pereira
Silva, Gabriel Henrique Campolina
Queiroz Junior, Celso Martins
Oliveira, Leonardo Camilo de
Lacerda, Larisse de Souza Barbosa
Gaggino, Jordane Clarisse Pimenta
Souza, Filipe Resende Oliveira de
Chaves, Ian de Meira
Passos, Ingredy Beatriz
Teixeira, Danielle Cunha
Silva, Paloma Graziele Bittencourt
Valadão, Priscila Aparecida Costa
Oliveira, Leonardo Rossi
Antunes, Maisa Mota
Figueiredo, André Felipe Almeida
Wnuk, Natália Teixeira
Temerozo, Jairo Ramos
Ferreira, André Costa
Cramer, Allysson
Oliveira, Cleida Aparecida
Carvalho, Ricardo Durães
Arns, Clarice Weis
Guimarães, Pedro Pires Goulart
Costa, Guilherme Mattos Jardim
Menezes, Gustavo Batista de
Guatimosim, Cristina
Silva, Glauber Santos Ferreira da
Souza, Thiago Moreno L.
Barrioni, Breno Rocha
Pereira, Marivalda de Magalhães
Sousa, Lirlândia Pires de
Teixeira, Mauro Martins
Costa, Vivian Vasconcelos
dc.subject.other.pt_BR.fl_str_mv Betacoronavírus
MHV-3
Infecção pulmonar
COVID-19
Modelo animal
Fator de necrose tumoral
topic Betacoronavírus
MHV-3
Infecção pulmonar
COVID-19
Modelo animal
Fator de necrose tumoral
Betacoronavirus
MHV-3
Lung infection
COVID-19
Animal model
Tumor necrosis factor
dc.subject.en.pt_BR.fl_str_mv Betacoronavirus
MHV-3
Lung infection
COVID-19
Animal model
Tumor necrosis factor
description Universidade Federal de Minas Gerais. Instituto de Ciências Biológicas. Departamento de Morfologia. Belo Horizonte, MG, Brasil.
publishDate 2021
dc.date.issued.fl_str_mv 2021
dc.date.accessioned.fl_str_mv 2022-01-13T12:56:44Z
dc.date.available.fl_str_mv 2022-01-13T12:56:44Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.citation.fl_str_mv ANDRADE, Ana Cláudia dos SantosPereira et al. A Biosafety Level 2 Mouse Model for Studying Betacoronavirus- Induced Acute Lung Damage and Systemic Manifestations. Journal of Virology, v. 95, n. 22, e01276-21, p. 1-18, Nov. 2021.
dc.identifier.uri.fl_str_mv https://www.arca.fiocruz.br/handle/icict/50746
dc.identifier.issn.pt_BR.fl_str_mv 1098-5514
dc.identifier.doi.none.fl_str_mv 10.1128/JVI.01276-21
dc.identifier.eissn.none.fl_str_mv 0022-538X
identifier_str_mv ANDRADE, Ana Cláudia dos SantosPereira et al. A Biosafety Level 2 Mouse Model for Studying Betacoronavirus- Induced Acute Lung Damage and Systemic Manifestations. Journal of Virology, v. 95, n. 22, e01276-21, p. 1-18, Nov. 2021.
1098-5514
10.1128/JVI.01276-21
0022-538X
url https://www.arca.fiocruz.br/handle/icict/50746
dc.language.iso.fl_str_mv eng
language eng
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv American Society for Microbiology
publisher.none.fl_str_mv American Society for Microbiology
dc.source.none.fl_str_mv reponame:Repositório Institucional da FIOCRUZ (ARCA)
instname:Fundação Oswaldo Cruz (FIOCRUZ)
instacron:FIOCRUZ
instname_str Fundação Oswaldo Cruz (FIOCRUZ)
instacron_str FIOCRUZ
institution FIOCRUZ
reponame_str Repositório Institucional da FIOCRUZ (ARCA)
collection Repositório Institucional da FIOCRUZ (ARCA)
bitstream.url.fl_str_mv https://www.arca.fiocruz.br/bitstream/icict/50746/2/Jaime_Temerozo_etal_IOC_2021.pdf
https://www.arca.fiocruz.br/bitstream/icict/50746/3/license.txt
bitstream.checksum.fl_str_mv 48c0d800e292f2c055dc1db1a34f05c5
5a560609d32a3863062d77ff32785d58
bitstream.checksumAlgorithm.fl_str_mv MD5
MD5
repository.name.fl_str_mv Repositório Institucional da FIOCRUZ (ARCA) - Fundação Oswaldo Cruz (FIOCRUZ)
repository.mail.fl_str_mv repositorio.arca@fiocruz.br
_version_ 1798324649116827648